Replacement therapy is useful for major bleeding episodes in people who do not respond to desmopressin and for patients with Type 2B and Type 3 disease. They are both derived from plasma and given by infusion. VWF concentrates are strongly preferred for safety reasons because they are treated to inactivate certain viruses, while cryoprecipiate is not. Humate-P is pasteurized to inactivate or remove certain viruses. Possible adverse events with Humate-P include allergic reaction, urticaria, chest tightness, rash, pruritus, and edema.
Anaphylactic reactions can occur in rare instances.
People with vWD should not receive high purity, plasma-derived factor VIII and recombinant factor VIII products. These medicines do not help the body form blood clots. Instead, they help protect clots and hold them in place. They are often used in combination with other medicines. 2 Clotting agents can be used to stop bleeding in the mouth, nose, or gastrointestinal tract.